Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.02.10.705086

Human milk contains a heterogeneous population of EVs and microRNAs that resist simulated digestion

Husseini, Z.·Pulido-Mateos, E. C.
View original source ↗Export metadata ↓

Abstract

Mothers milk is known for its crucial roles in infant health and development. Probably the most commonly studied effects of milk are those on an infants intestinal barrier, metabolism, and immunity. While these functions of milk were mostly attributed to its protein and fat content, recent evidence points to a potential role of milk microRNAs in these processes. MicroRNAs are small non-coding RNAs that can fine-tune gene expression at the post-transcriptional level. Human milk (HM) is rich in microRNAs, which are mainly found associated with milk extracellular vesicles (EVs). HM microRNAs are proposed to transfer from mother to infant via breastfeeding and execute gene regulatory functions in infant cells. For microRNAs to be able to act as "genetic programmers" rather than mere nutritional molecules, they should resist digestion in the infants gastrointestinal tract. Milk EVs are believed to protect microRNAs against degradation and facilitate their delivery to the cells. Here, we used two lots of pasteurized HM that were originally destined for human milk banks. We showed that HM contains different populations of EVs with different physicochemical properties, similar to those previously identified in commercial bovine milk. We also showed that these EVs, which are often discarded, contain the majority of HM microRNAs. Finally, we showed that three highly abundant milk microRNAs resisted differentially to infants simulated digestion conditions, with a relatively small number of microRNAs surviving a two-hour digestion. Milk microRNA copy numbers surviving digestion may be too low to influence gene expression in infant cells. HighlightsO_LIPasteurized HM contains heterogeneous populations of EVs. C_LIO_LIThese EVs associate with the majority of HM microRNAs. C_LIO_LIDifferent microRNAs show varying stability during infant digestion. C_LIO_LIThe copy number of milk miR-148a-3p surviving digestion might be too low to influence gene expression in infant cells. C_LI

Explore related subjects

molecular biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Husseini, Z., Pulido-Mateos, E. C.. 2026-02-11. Human milk contains a heterogeneous population of EVs and microRNAs that resist simulated digestion. https://doi.org/10.64898/2026.02.10.705086

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Single-AAV-mediated cardiomyocyte-specific adenine base editing ameliorates cardiac hypertrophy in vivo

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, frequently accompanied by cardiac hypercontractility, diastolic dysfunction, heart failure and sudden cardiac death. The disease is predominantly caused by pathogenic variants in genes encoding sarcomeric proteins and current therapeutic strategies largely focus on symptom management. Adeno-associated virus-based (AAV) delivery of base editing tools has emerged as an alternative strategy that acts directly on the genetic cause of disease. However, canonical SpCas9-based editors are too large to package into a single-AAV vector which mandates dual-AAV approaches that require higher overall vector doses with elevated toxicity risk and increased manufacturing costs. Here, we report the development and application of a single vector approach for cardiomyocyte-specific adenine base editing to correct a Dutch founder mutation in MYBPC3 (c.2827C>T, p.Arg943Ter) that causes HCM. We systematically compared compact base editors in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and selected the most efficient configuration, which reversed disease-associated hypercontractility in engineered human myocardium (EHM). To fit the editor/guide construct in a single-AAV vector, we screened a library of rationally designed small chimeric promoters and identified 6C2 to effectively drive expression in hiPSC-CMs and cardiac tissue of both mice and non-human primates (NHP) with exceptional specificity. Delivered in a single next-generation cardiotropic AAV capsid, we achieved therapeutic correction in an HCM mouse model at doses 20-fold below published dual-AAV cardiomyopathy base editing approaches. These results establish cardiomyocyte-specific, single vector-mediated base editing as a viable therapeutic strategy for inherited cardiomyopathies.

molecular biology↗
bioRxiv2026

Engineered Miniature ParTasR Enables Efficient PAMless Genome Editing

TIGR-Tas system holds great promise for genome-engineering applications owing to its compact size and PAMless targeting capability. However, its low editing efficiency in mammalian cells severely limits its broader utility. Here, we engineered a highly active variant of ParTasR, termed eTasR, through structure-guided rational design of ParTasR combined with fusion to the exonuclease TREX2. eTasR increased mammalian editing efficiency from the original 4.29% to 48.94% with an average 26.52-fold increase, significantly surpassing the efficiency of SpRY, a reported version of PAM-free nuclease. More importantly, single-AAV delivery enabled efficient Hpd disruption in vivo, resulting in robust phenotypic rescue. Thus, eTasR provides a compact, PAMless and highly efficient platform for genome editing and therapeutic applications.

molecular biology↗
bioRxiv2026

Enhancing pancreatic islet cell survival via NMDAR antagonist-driven ROR1 activation as revealed by phosphoproteomics

NMDA receptors (NMDARs) control function and survival not only of neurons, but also of insulin-producing pancreatic beta cells. Since insufficient insulin secretion and beta cell death are key events during diabetes development, targeting NMDARs offers a therapeutic approach. Specifically, the NMDAR antagonist dextrorphan (DXO) increases glucose-stimulated insulin secretion in clinical trials. Furthermore, treatment with DXO or optimized DXO derivatives prevents pancreatic islet cell death upon diabetogenic insults. Nonetheless, the signaling pathways induced by NMDAR inhibition are poorly understood. Here, we use complementary approaches, phosphoproteomics and tyrosine kinase profiling, to demonstrate that DXO and its derivatives rapidly regulate multiple intracellular signaling clusters, including mTOR and ERK signaling, in pancreatic islets. Notably, mTOR inhibition, but not ERK inhibition, is sufficient to negate DXO's protective effects. Further, we show that activation of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) is a universal event upon NMDAR inhibition in islets. Simultaneous knockdown of Ror1/ROR1 and its paralogue Ror2/ROR2 compromises the viability of both mouse and human islets, highlighting the ROR1/2 signaling axis as a promising avenue for enhancing beta cell survival.

molecular biology↗